Peptide modulation of allergen-specific immune responses.
In vitro peptide stimulation of allergen-reactive T-helper type 1 and type 0 cells, in the absence of costimulatory signals, induces anergy that is accompanied by the modulation of cell surface phenotype and changes in cytokine production. In experimental animal models, the administration of allergen-derived peptides may result in the downregulation of cytokine and antibody production, which is preceded by transient activation of CD4+ T cells, without the induction of effector immunity. Preliminary results of clinical trials using allergen-derived peptides for desensitization are becoming available and should provide some insight into the efficacy of peptide therapy in man.
Hoyne
G F
GF
Imperial College of Science, Technology and Medicine, London, UK.
Kristensen
N M
NM
Yssel
H
H
Lamb
J R
JR
D016525:Antigenic Modulation; D016207:Cytokines / Q000096:biosynthesis; D003888:Desensitization, Immunologic; D000939:Epitopes; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000276:immunology*; D007108:Immune Tolerance; D018448:Models, Immunological; D010455:Peptides / Q000276:immunology*; D018417:Th1 Cells / Q000276:immunology*
D016207:Cytokines; D000939:Epitopes; D010455:Peptides